查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球肾上腺脑白质营养不良市场：按地区和国家分析和预测（2025 年至 2035 年）
市场调查报告书
商品编码
1735554

全球肾上腺脑白质营养不良市场：按地区和国家分析和预测（2025 年至 2035 年）

Adrenoleukodystrophy Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

全球肾上腺脑白质营养不良市场目前正处于其生命週期的成长阶段。

在经历了治疗方法有限和认知度较低的导入期之后，随着基于基因疗法的治疗方法和创新药物疗法的进步，市场对该疾病的兴趣日益浓厚。新生儿筛检计划等诊断技术的改进使得更早发现疾病成为可能，从而增加了对治疗性介入的需求。此外，孤儿药计画和政府对罕见疾病的支持力度也在推动市场成长。然而，市场仍然面临着若干挑战，最明显的是治疗费用高昂以及由于患者数量相对较少导致的市场规模有限。这些因素可能会阻碍市场的快速扩张。总体而言，市场目前正在成长但仍高度专业化，预计持续的研究和开发将促进整个罕见疾病领域的发展。

影响

  • 预计预测期内，对肾上腺脑白质营养不良症治疗的需求不断增长将推动全球肾上腺脑白质营养不良症市场的成长
  • 由于标靶治疗的进步、认知度和诊断率的提高、临床开发平臺的扩大、医疗基础设施的改善以及专科治疗机会的改善，全球 ALD 市场预计将在未来显着增长。

近期动态

  • 研究活动：2024 年 12 月，Minoryx Therapeutics 和 Neuraxpharm Group 宣布，leriglitazone 在针对患有大脑肾上腺脑白质营养不良的儿科患者的 NEXUS 研究中达到了其主要终点。

本报告调查了全球肾上腺脑白质营养不良市场，并总结了主要趋势、影响市场的因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第 1 章全球肾上腺脑白质营养不良市场概述

  • 产业展望
    • 市场概况与生态系统
    • 市场趋势
    • 肾上腺脑白质营养不良的流行病学分析
    • 临床试验
    • 监管状况/合规性
  • 市场动态
    • 影响分析
    • 市场驱动因素
    • 市场限制
    • 市场机会

2. 全球肾上腺脑白质营养不良症市场（按地区）

  • 北美洲
  • 欧洲
  • 亚太地区
    • 市场动态
    • 市场规模及预测

3. 全球肾上腺脑白质营养不良市场：竞争基准化分析与公司简介

  • 竞争格局
    • 各公司主要策略及发展
    • 重大进展分析
  • 公司简介
    • bluebird bio
    • Minoryx Therapeutics, SL
    • MedDay Pharmaceuticals
    • Viking Therapeutics
    • Neuraxpharm Group

第四章调查方法

Product Code: BHL2940SA

Industry Overview

The global adrenoleukodystrophy market is currently in the growth stage of its lifecycle. Having transitioned from the introduction phase, where treatment options were limited and awareness was low, the market is now experiencing increased interest due to advances in gene therapy-based treatments and innovative drug therapies. Rising diagnostic capabilities, such as newborn screening programs, have contributed to earlier detection, driving demand for therapeutic interventions. Furthermore, the emergence of orphan drug programs and government support for rare diseases has spurred market growth. However, the market still faces challenges, including high treatment costs and a relatively small patient base, which may limit rapid expansion. Overall, while the market is growing, it remains highly specialized and will continue to evolve the rare disease landscape with ongoing research and development.

Impact

  • Increasing demand for adrenoleukodystrophy therapies is anticipated to support the growth of the global adrenoleukodystrophy market during the forecast period 2025-2035.
  • The global adrenoleukodystrophy market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline, alongside advancements in healthcare infrastructure and access to specialized treatments.

Recent Developments

  • Research Activities: In December 2024, Minoryx Therapeutics and Neuraxpharm Group announced that leriglitazone met the primary endpoint in the NEXUS trial for paediatric patients with cerebral adrenoleukodystrophy (cALD).

Demand - Drivers and Limitations

Drivers:

  • Increasing Prevalence of Adrenoleukodystrophy
  • Advancements in Treatment Options
  • Growing Research and Investment in Rare Diseases

Limitations:

  • High Treatment Costs
  • Limited Awareness in Developing Regions

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Innovations in the global adrenoleukodystrophy market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Minoryx Therapeutics and NeuraxPharm, have been involved in the development of therapies for adrenoleukodystrophy.

Competitive Strategy: Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.

Some of the prominent names established in this market are:

  • bluebird bio
  • Minoryx Therapeutics, S.L.
  • MedDay Pharmaceuticals
  • Viking Therapeutics
  • Neuraxpharm Group

Table of Contents

Executive Summary

Scope of Study

1. Global Adrenoleukodystrophy Market Overview

  • 1.1 Industry Outlook
    • 1.1.1 Market Overview and Ecosystem
    • 1.1.2 Market Trends
    • 1.1.3 Epidemiological Analysis of Adrenoleukodystrophy
    • 1.1.4 Clinical Trials
      • 1.1.4.1 By Phase
      • 1.1.4.2 By Sponsor Type
    • 1.1.5 Regulatory Landscape / Compliance
  • 1.2 Market Dynamics
    • 1.2.1 Impact Analysis
    • 1.2.2 Market Drivers
    • 1.2.3 Market Restraints
    • 1.2.4 Market Opportunities

2. Global Adrenoleukodystrophy Market (By Region), $Million, 2023-2035

  • 2.1 North America
    • 2.1.1 Market Dynamics
    • 2.1.2 Market Size and Forecast
      • 2.1.2.1 North America Adrenoleukodystrophy Market (by Country)
        • 2.1.2.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Market Dynamics
    • 2.2.2 Market Size and Forecast
      • 2.2.2.1 Europe Adrenoleukodystrophy Market (by Country)
        • 2.2.2.1.1 U.K.
        • 2.2.2.1.2 Germany
        • 2.2.2.1.3 France
        • 2.2.2.1.4 Italy
        • 2.2.2.1.5 Spain
  • 2.3 Asia-Pacific
    • 2.3.1 Market Dynamics
    • 2.3.2 Market Size and Forecast
      • 2.3.2.1 Asia-Pacific Adrenoleukodystrophy Market (by Country)
        • 2.3.2.1.1 Japan

3. Global Adrenoleukodystrophy Market - Competitive Benchmarking and Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 Key Strategies and Developments by Company
      • 3.1.1.1 Funding Activities
      • 3.1.1.2 Mergers and Acquisitions
      • 3.1.1.3 Regulatory Approvals
      • 3.1.1.4 Partnerships, Collaborations and Business Expansions
    • 3.1.2 Key Developments Analysis
  • 3.2 Company Profiles
    • 3.2.1 bluebird bio
      • 3.2.1.1 Company Overview
      • 3.2.1.2 Product Portfolio
      • 3.2.1.3 Target Customers/End Users
      • 3.2.1.4 Analyst View
    • 3.2.2 Minoryx Therapeutics, S.L.
      • 3.2.2.1 Company Overview
      • 3.2.2.2 Product Portfolio
      • 3.2.2.3 Target Customers/End Users
      • 3.2.2.4 Analyst View
    • 3.2.3 MedDay Pharmaceuticals
      • 3.2.3.1 Company Overview
      • 3.2.3.2 Product Portfolio
      • 3.2.3.3 Target Customers/End Users
      • 3.2.3.4 Analyst View
    • 3.2.4 Viking Therapeutics
      • 3.2.4.1 Company Overview
      • 3.2.4.2 Product Portfolio
      • 3.2.4.3 Target Customers/End Users
      • 3.2.4.4 Analyst View
    • 3.2.5 Neuraxpharm Group
      • 3.2.5.1 Company Overview
      • 3.2.5.2 Product Portfolio
      • 3.2.5.3 Target Customers/End Users
      • 3.2.5.4 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Adrenoleukodystrophy Market, Market Overview
  • Figure: Global Adrenoleukodystrophy Market, Epidemiological Analysis, U.S.
  • Figure: Global Adrenoleukodystrophy Market Coverage
  • Figure: Global Adrenoleukodystrophy Market Key Trends, Impact Analysis, 2023-2035
  • Figure: Global Adrenoleukodystrophy Market, Competitive Landscape, January 2022-April 2025

List of Tables

  • Table: Global Adrenoleukodystrophy Market, Regulatory Scenario
  • Table: Global Adrenoleukodystrophy Market Dynamics, Impact Analysis
  • Table: Global Adrenoleukodystrophy Market (by Region), $Million, 2023-2035